HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention

202233 citationsJournal Articlebronze Open Access

Authors

Susan H. Eshleman · Johns Hopkins University

Jessica M. Fogel · Johns Hopkins University

Elias K. Halvas · University of Pittsburgh

Estelle Piwowar‐Manning · Johns Hopkins University

Mark A. Marzinke · Johns Hopkins University

Ryan Kofron · University of California, Los Angeles

Zhe Wang

Abstract

When using CAB-LA PrEP, earlier detection of HIV infection with a sensitive RNA assay may allow for earlier treatment initiation with the potential to reduce INSTI resistance risk. Further studies are needed to evaluate the value and feasibility of HIV RNA testing with CAB-LA PrEP.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Infectious Diseases

Volume 226, Issue 12, pp. 2170-2180

DOI: 10.1093/infdis/jiac415

Field-Weighted Citation Impact: 3.24